Hims & Hers Health (HIMS) Competitors $44.48 +0.52 (+1.17%) As of 03:38 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock HIMS vs. NTRA, GH, RDNT, OPCH, SHC, BTSG, WGS, CON, SGRY, and PRVAShould you be buying Hims & Hers Health stock or one of its competitors? The main competitors of Hims & Hers Health include Natera (NTRA), Guardant Health (GH), RadNet (RDNT), Option Care Health (OPCH), Sotera Health (SHC), BrightSpring Health Services (BTSG), GeneDx (WGS), Concentra Group Holdings Parent (CON), Surgery Partners (SGRY), and Privia Health Group (PRVA). These companies are all part of the "healthcare" industry. Hims & Hers Health vs. Its Competitors Natera Guardant Health RadNet Option Care Health Sotera Health BrightSpring Health Services GeneDx Concentra Group Holdings Parent Surgery Partners Privia Health Group Hims & Hers Health (NYSE:HIMS) and Natera (NASDAQ:NTRA) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk. Do institutionals & insiders have more ownership in HIMS or NTRA? 63.5% of Hims & Hers Health shares are owned by institutional investors. Comparatively, 99.9% of Natera shares are owned by institutional investors. 13.7% of Hims & Hers Health shares are owned by insiders. Comparatively, 5.6% of Natera shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is HIMS or NTRA more profitable? Hims & Hers Health has a net margin of 9.63% compared to Natera's net margin of -12.89%. Hims & Hers Health's return on equity of 26.26% beat Natera's return on equity.Company Net Margins Return on Equity Return on Assets Hims & Hers Health9.63% 26.26% 13.06% Natera -12.89%-22.22%-15.03% Do analysts prefer HIMS or NTRA? Hims & Hers Health currently has a consensus target price of $38.92, suggesting a potential downside of 12.50%. Natera has a consensus target price of $193.19, suggesting a potential upside of 16.51%. Given Natera's stronger consensus rating and higher possible upside, analysts clearly believe Natera is more favorable than Hims & Hers Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hims & Hers Health 3 Sell rating(s) 8 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 1.92Natera 0 Sell rating(s) 0 Hold rating(s) 17 Buy rating(s) 1 Strong Buy rating(s) 3.06 Which has preferable earnings and valuation, HIMS or NTRA? Hims & Hers Health has higher earnings, but lower revenue than Natera. Natera is trading at a lower price-to-earnings ratio than Hims & Hers Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHims & Hers Health$1.48B6.81$126.04M$0.8055.60Natera$1.70B13.41-$190.43M-$1.91-86.81 Does the media favor HIMS or NTRA? In the previous week, Hims & Hers Health had 62 more articles in the media than Natera. MarketBeat recorded 92 mentions for Hims & Hers Health and 30 mentions for Natera. Natera's average media sentiment score of 1.12 beat Hims & Hers Health's score of 0.23 indicating that Natera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hims & Hers Health 15 Very Positive mention(s) 13 Positive mention(s) 51 Neutral mention(s) 8 Negative mention(s) 2 Very Negative mention(s) Neutral Natera 21 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, HIMS or NTRA? Hims & Hers Health has a beta of 2.08, indicating that its stock price is 108% more volatile than the S&P 500. Comparatively, Natera has a beta of 1.76, indicating that its stock price is 76% more volatile than the S&P 500. SummaryHims & Hers Health beats Natera on 9 of the 17 factors compared between the two stocks. Get Hims & Hers Health News Delivered to You Automatically Sign up to receive the latest news and ratings for HIMS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HIMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HIMS vs. The Competition Export to ExcelMetricHims & Hers HealthMEDICAL INFO SYS IndustryMedical SectorNYSE ExchangeMarket Cap$10.06B$2.14B$5.82B$21.18BDividend YieldN/AN/A3.84%3.59%P/E Ratio55.6138.4831.1429.13Price / Sales6.8113.79475.4854.50Price / Cash123.1850.7737.1523.84Price / Book17.866.709.115.44Net Income$126.04M-$63.67M$3.26B$992.10M7 Day Performance-3.50%4.26%1.94%2.56%1 Month Performance-10.92%2.85%4.91%2.46%1 Year Performance170.37%27.66%31.21%12.98% Hims & Hers Health Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HIMSHims & Hers Health2.8187 of 5 stars$44.48+1.2%$38.92-12.5%+164.5%$10.06B$1.48B55.611,637Trending NewsAnalyst DowngradeInsider TradeGap DownNTRANatera3.4297 of 5 stars$162.25-0.5%$193.19+19.1%+32.8%$22.23B$1.96B-84.814,434Positive NewsGHGuardant Health3.3562 of 5 stars$59.39+0.9%$57.50-3.2%+116.8%$7.41B$739.02M-17.732,021RDNTRadNet3.3155 of 5 stars$66.54-1.3%$71.60+7.6%+8.7%$5.12B$1.83B-332.9911,021News CoverageInsider TradeOPCHOption Care Health4.5637 of 5 stars$27.99-1.2%$35.75+27.7%-10.3%$4.54B$5.00B22.388,088Positive NewsInsider TradeGap UpSHCSotera Health1.3945 of 5 stars$15.79+0.3%$16.00+1.4%+3.7%$4.48B$1.10B197.213,000News CoverageBTSGBrightSpring Health Services1.6779 of 5 stars$23.00+2.5%$25.67+11.6%+96.2%$4.08B$11.27B74.2935,000Positive NewsWGSGeneDx2.215 of 5 stars$126.16-0.2%$101.63-19.4%+249.9%$3.63B$305.45M2,526.401,200CONConcentra Group Holdings Parent2.3798 of 5 stars$22.90-1.5%$28.50+24.5%-1.6%$2.93B$1.90B19.2211,250News CoveragePositive NewsSGRYSurgery Partners2.8546 of 5 stars$22.72-0.4%$33.00+45.2%-18.2%$2.91B$3.11B-15.9015,000Positive NewsPRVAPrivia Health Group4.2233 of 5 stars$21.48+1.0%$28.00+30.4%+9.8%$2.64B$1.74B195.211,140News CoveragePositive NewsAnalyst Upgrade Related Companies and Tools Related Companies NTRA Competitors GH Competitors RDNT Competitors OPCH Competitors SHC Competitors BTSG Competitors WGS Competitors CON Competitors SGRY Competitors PRVA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:HIMS) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersSilver’s Still Under $35… For Now.Silver is trading around $33—but insiders are betting on a $70 breakout by year’s end. With supply shrinkin...GoldenCrest Metals | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hims & Hers Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hims & Hers Health With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access